Professional Documents
Culture Documents
Agenda
Overview of Piramal Healthcare Pharma Solutions Critical Care Consumer Products Business Life Sciences Financial Services Special investments
2
Pharma Business
Pharma Solutions
Partners with MNC pharma cos to service their mfg & development needs Sales Rs. 10.2 bn
Critical Care
Sells anesthetic products to hospitals globally
OTC
Life Sciences
Works in 4 TA: Oncology, Diabetes, Inflammation Infectious Diseases Has a pipeline of 16 compounds with 8 in clinical trials Received approval for cartilage repair gel BST-Cargel
NBFC
NBFC focused on lending to Real estate sector Current book of Rs. 1.3 billion
IndiaReit
A Real Estate Investment Trust with domestic and offshore fund Total AUM Rs. 38 billion
4
Pharma Solutions
Market Characteristics
Global Outsourcing market estimated to be USD 32 billion, growing at 12% Market share of India extremely low Lower costs and high quality manufacturing skill presents compelling Cost pressures on big pharma due to patent expiries leading to
64.0
5.3
U SD B n
4 3 2 1 0 1.8
31.9
Year 2017
Year 2011
Year 2017
Clinical Trials Formulations Medicinal & Synthetic Chemistry Services India Ahmedabad API Canada Torcan UK Morpeth, Morpeth India Ennore Formulations UK Morpeth India - Ahmedabad API
Canada - Torcan UK Morpeth, India Ennore, Formulations UK Morpeth India Ahmedabad 9M FY2012 963 585 378
Sales break-up (Rs. In crores) Pharma Solutions From assets in India From assets outside India
UNITED KINGDOM
Morpeth API development & manufacturing Formulation development Commercial formulation manufacturing Clinical Trial supplies & distribution Grangemouth Antibody Drug Conjugates development & manufacturing
RM supplies
INDIA
Mumbai R&D API development Formulation development Chennai API development & manufacturing Hyderabad API manufacturing
CHINA
Shanghai Sourcing Office
Ahmedabad Drug Discovery Services Formulations Development Clinical Trial manufacturing Pithampur Commercial formulation manufacturing 8
Critical Care
2006
Addressable Market Opportunity $ Million
2011
2016
100
550
1,800
10
Products
Products Manufactured
Approvals/Certific ation USFDA, AFSSAPS US FDA, WHO, UKMHRA, MCC WHO USFDA
Bethlehem Digwal
9M FY2012 281
Growth 3.3%
Desflurane
Sevoflurane
Enflurane
Isoflurane
Halothane
Propofol
Haemaccel
11
OTC Business
12
13
Life Sciences
14
15
BST-CarGel: An overview
A novel bioscaffold for advanced cartilage regeneration that has clinically demonstrated consistently higher quality cartilage repair An EU class III medical device, it is a liquid scaffold which, combined with the patients whole blood, is then implanted into a debrided cartilage lesion prepared with bone marrow access Received European CE mark regulatory approval in April 2012 Plans to commercially launch in the fourth quarter of the 2012 calendar year Filed for regulatory approval to sell in Canada and will soon file in India
MRI of patient treated with CarGel
Damaged Cartilage Before Treatment Cartilage After Treatment
Current European Market Potential The CE mark enables us to access a potential $ 200 mn market in Europe. While we can sell in all EU countries, the largest markets in Europe for BST-CarGel are: UK, Germany, France, Spain, and Italy
Financial Services
18
IndiaReit
Advisor to Offshore and Domestic Real estate funds AUM: Rs. 3,800 crores
PHL Finance
NBFC lending to Real Estate, Promoter Financing, Hospitals, Educational Institutes etc. Team in place for Real Estate Funding, being set up for other segments Operations commenced; current loan book of Rs. 131 crores
Infra NBFC
Regulatory approvals awaited
19
Realized exits across funds Exits commenced since October 2008 Valuations in sync with guidance and exit delivery Estimate 2.22x pre-tax money multiple on valued portfolio (March 11) Ability to profitably deploy large pools of capital; Over USD 650Mn in 4 years First to declare independent valuations First to commence exits in investee projects First to round trip investments across all fund offerings First to manage third party portfolio
Work commenced on majority projects No partners litigations No land issues No credit default Visible cash flows Work linked to off-take
Comprehensive Experience 5 Top Tier 1 cities 8 Local partners 23 Projects 53.7m sq ft of Saleable area currently under development 20
20
PHLs commitment to these new funds will be 8 10 percent IndiaReit to look for special mandates like the investment management mandate that it has from Trinity Capital PLC under which it manages US $ 200 mn of assets Investment in IndiaReit to generate ROE of 18-20% from 2014 onwards
21
22
Special Investments
23
Special Investments
PHL to invest surplus funds in investments that give:
o o o o o o
minority equity stake global companies in India high growth sectors short to medium term Minimal risk ROE: 17-20% p.a.
PHL has increased its stake in Vodafone Essar to 11% with the total investment of $ 1.2 billion The partnership underscores trust placed by global companies in Piramal values, ethics, corporate governance and good reputation
24
Thank you
For further details contact: Sagar Gokani sagar.gokani@piramal.com Prasad Mhatre prasad.mhatre@piramal.com
25
Back-up slides
26
Note: Foreign exchange gain (mainly on Abbott receivables) included in OPBIDTA of Q3 FY2012 and 9MFY2012 of Rs. 28.0 crores and 206.9 crores
27
Period ended- Consolidated Equity capital Reserves & Surplus Networth Minority Interest Deferred tax liability (Net) Loan funds Total Net fixed assets Investments Net current assets Inventories Sundry debtors Other current assets Current liabilities Total
As at 31-Dec-11 34.5 11,541.8 11,576.4 8.9 60.1 1,172.9 12,818.2 1,971.9 3,877.0 6,969.4 495.9 396.8 7,404.1 1,327.3 12,818.2
As at 30-Sep-11 33.4 11,879.2 11,912.7 7.7 46.1 1,088.9 13,055.4 1,717.9 3,917.5 7,420.0 455.6 351.9 7,546.2 933.7 13,055.4
28
1. Other current assets include amount of Rs. 6,373 crores as receivable from Abbott towards sale of Healthcare Solutions business